Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.54 |
| ▸ | NOS2 | P35228 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 6/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | HEXA | P06865 | 1/20 | 0.38 |
| ▸ | HEXB | P07686 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6361284 | 0.87 | NOS2 (0.59) | NOS3NOS2HRH3HRH4PDPK1 | |
| SCHEMBL1577063 | 0.85 | NOS2 (0.52) | NOS3NOS2HRH3HRH4HSP90AB1 | |
| SCHEMBL718227 | 0.84 | HSP90AB1 (0.56) | NOS3NOS2HRH3HRH4KDM4E | |
| SCHEMBL5748988 | 0.84 | HRH3 (0.46) | NOS3NOS2HRH3HRH4PDPK1 | |
| SCHEMBL218379 | 0.84 | HRH3 (0.46) | NOS3NOS2HRH3HRH4PDPK1 | |
| SCHEMBL12986265 | 0.80 | HRH3 (0.44) | NOS3NOS2HRH3HRH4PDPK1 | |
| SCHEMBL26977850 | 0.80 | NPC1 (0.47) | NOS3NOS2HRH3HRH4PDPK1 | |
| SCHEMBL10863598 | 0.79 | NOS2 (0.57) | NOS3NOS2HRH3HRH4PDPK1 | |
| SCHEMBL26069745 | 0.79 | HSP90AA1 (0.58) | NOS3NOS2HRH3HRH4PDPK1 | |
| SCHEMBL7274937 | 0.78 | NOS2 (0.54) | NOS3NOS2HRH3HRH4HEXA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| WO-2011039276-A1 | OXATHIAZINYL(HET)ARYLSULFONYLUREAS, PROCESSES AND INTERMEDIATES FOR PREPARATION THEREOF AND USE THEREOF AS CROP PROTECTION AGENTS AND CROP GROWTH REGULATORS | BAYER CROPSCIENCE AG (DE) | 2011-04-07 | — | — | WO | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| US-5847126-A | N-azinyl-N'-(het) arylsulphonyl-ureas | BAYER AKTIENGESELLSCHAFT (DE) | 1998-12-08 | — | — | US | disclosed |
| EP-0645386-B1 | N-Azinyl-N'-(het)arylsulfonylureas as herbicides | BAYER AG (DE) | 1997-12-29 | — | — | EP | disclosed |
| US-5696257-A | INTERMEDIATES FOR HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-09 | — | — | US | disclosed |
| US-5580842-A | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-12-03 | — | — | US | disclosed |
| US-5476936-A | Herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 1995-12-19 | — | — | US | disclosed |
| CN-1108656-A | N-azinyl-N'-(HET)arylsulphonyl-ureas | BAYER AG (DE) | 1995-09-20 | — | — | CN | disclosed |
| EP-0645386-A1 | N-Azinyl-N'-(het)arylsulfonylureas as herbicides | BAYER AG (DE) | 1995-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | NOS3 1009/4885NOS2 2066/4885HRH3 957/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | NOS3 1009/4885NOS2 2066/4885HRH3 957/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | NOS3 1009/4885NOS2 2066/4885HRH3 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.